AmbioPharm, Inc. (AmbioPharm), a peptide manufacturer and developer, announced it is expanding its operations in Aiken County.
The company’s $118.96 million investment will create 202 jobs, according to the South Carolina Department of Commerce.
“As the global demand for peptide therapeutics accelerates, the need for dependable U.S. manufacturing is extremely important. This expansion enhances our ability to support our client-partners with scalable, high-quality production while creating new opportunities for skilled talent in Aiken County,” said-AmbioPharm CEO Brian Gregg.
Founded in 2005, AmbioPharm is headquartered in North Augusta and specializes in developing highly efficient peptide manufacturing processes for peptide-based active pharmaceutical ingredients (APIs) at small to very large scales.
The company manufactures new chemical entities (NCEs) and peptide APIs under current good manufacturing practice (GMP) regulations for clients worldwide.
Officials said that as part of its expansion, AmbioPharm will construct a modular manufacturing building at its existing South Carolina campus, located at 1024 Dittman Court in North Augusta.
The facility will offer commercial-scale GMP synthesis, solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS) and hybrid approaches, all supported by semi-automated production systems and advanced solvent delivery infrastructure.
Operations are expected to be online by the end of 2027. Those interested in joining the AmbioPharm team should go to the company’s careers page.
Comments
No comments on this item Please log in to comment by clicking here